Fisetin and Polymeric Micelles Encapsulating Fisetin Exhibit Potent Cytotoxic Effects Towards Ovarian Cancer Cells

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2018 Mar 17

PMID 29544480

Citations 19

Authors

Xue Xiao

Juan Zou

Yin Fang

Yibo Meng

Chao Xiao

Jiaxin Fu

Shiyu Liu

Peng Bai

Yuan Yao

Affiliations

Soon will be listed here.

Abstract

Background: The anti-tumor activities of Natural compounds and their derivatives are of great interest to pharmaceutical industries. Fisetin is one of prospective natural compounds in this regard but unfortunately with poor hydrophilicity.

Methods: The effects of unmodified and modified fisetin in cultured ovarian cancer cells were compared by transmission electronmicroscopy to determine apoptotic bodies, MTT assay to quantitate cell numbers, and fluorescence activated cell sorting analyse of various markers to determine the apoptotic state. In addition, the efficacy of fisetin and fisetin-micelles in vivo was determined by using immunocompromised mice. Apoptosis was measured by established markers using both western blot analysis and immunochemistry. Angiogenesis in a xenograft mouse model carring SKOV3 cells was evaluated by color Doppler ultrasound and immunohistochemistry.

Result: Multiple lines of evidence indicated that fisetin and fisetin micelles induce apoptosis in ovarian cancer cells in a dose-dependent manner. Histological analysis, terminal deoxynucleotidyltransferase-mediated nick-end labeling assay, western blot, immunohistochemical detection and microvessel density detection demonstrated that fisetin and fisetin micelles induced increased tumor apoptosis, proliferation suppression and antiangiogenesis activities.

Conclusion: As far as we know, the present study is the first time to demonstrate the potency of both fisetin and fisetin micelles inducing apoptosis in ovarian cancer cells. Further studies will be needed to validate the therapeutic potential of fisetin and fisetin micelles in ovarian cancer treatment.

Citing Articles

Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges.

Gajos-Michniewicz A, Czyz M Int J Mol Sci. 2024; 25(23).

PMID: 39684513 PMC: 11641450. DOI: 10.3390/ijms252312804.

PLGA-PEG-c(RGDfK)- E Micelles With a Therapeutic Potential for Targeting Ovarian Cancer.

Chen X, Wan H, Lu L, Li R, Sun B, Ren J IET Nanobiotechnol. 2024; 2024:7136323.

PMID: 39649540 PMC: 11623995. DOI: 10.1049/nbt2/7136323.

A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.

Li Y, Shen Q, Feng L, Zhang C, Jiang X, Liu F Front Immunol. 2024; 15:1427573.

PMID: 39464892 PMC: 11502327. DOI: 10.3389/fimmu.2024.1427573.

Cubosomal nanoformulation increase dissolution and anticancer activity of Fisetin in A549 lung cancer cells.

Kedar T, Jalalpure S, Kurangi B Ther Deliv. 2024; .

PMID: 38639652 PMC: 11160450. DOI: 10.4155/tde-2023-0146.

Role of Fisetin in Selected Malignant Neoplasms in Women.

Markowska A, Antoszczak M, Kacprzak K, Markowska J, Huczynski A Nutrients. 2023; 15(21).

PMID: 37960338 PMC: 10648688. DOI: 10.3390/nu15214686.

References

Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C . Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011; 10(2):255-68. DOI: 10.1158/1535-7163.MCT-10-0606. View

Ying T, Yang S, Tsai S, Hsieh S, Huang Y, Bau D . Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway. Arch Toxicol. 2011; 86(2):263-73. DOI: 10.1007/s00204-011-0754-6. View

Chen Y, Wu Q, Song L, He T, Li Y, Li L . Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer. ACS Appl Mater Interfaces. 2014; 7(1):534-42. DOI: 10.1021/am5066893. View

Katalinic M, Rusak G, Domacinovic Barovic J, Sinko G, Jelic D, Antolovic R . Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem. 2009; 45(1):186-92. DOI: 10.1016/j.ejmech.2009.09.041. View

Khan N, Afaq F, Khusro F, Adhami V, Suh Y, Mukhtar H . Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer. 2011; 130(7):1695-705. PMC: 3267899. DOI: 10.1002/ijc.26178. View

Chen W, Lee Y, Yu Y, Hsaio C, Yen J, Yu S . Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int J Radiat Oncol Biol Phys. 2010; 77(5):1527-35. DOI: 10.1016/j.ijrobp.2010.02.043. View

Anso E, Zuazo A, Irigoyen M, Urdaci M, Rouzaut A, Martinez-Irujo J . Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol. 2010; 79(11):1600-9. DOI: 10.1016/j.bcp.2010.02.004. View

Haddad A, Fleshner N, Nelson C, Saour B, Musquera M, Venkateswaran V . Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr Cancer. 2010; 62(5):668-81. DOI: 10.1080/01635581003605524. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

10.

Echarri Gonzalez M, Green R, Muggia F . Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?. Oncology (Williston Park). 2011; 25(2):156-65, 170. View

11.

Wu M, Hung S, Fu S . Immunosuppressive effects of fisetin in ovalbumin-induced asthma through inhibition of NF-κB activity. J Agric Food Chem. 2011; 59(19):10496-504. DOI: 10.1021/jf202756f. View

12.

Hopkins T, Mura M, Al-Ashtal H, Lahr R, Abd-Latip N, Sweeney K . The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016; 44(3):1227-46. PMC: 4756840. DOI: 10.1093/nar/gkv1515. View

13.

Suh Y, Afaq F, Johnson J, Mukhtar H . A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis. 2008; 30(2):300-7. PMC: 2722149. DOI: 10.1093/carcin/bgn269. View

14.

Li Q, Lee R, Liang H, Zhong Y, Reed E . Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol. 2013; 30(1):424. PMC: 3737577. DOI: 10.1007/s12032-012-0424-4. View

15.

Hanneken A, Lin F, Johnson J, Maher P . Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 2006; 47(7):3164-77. DOI: 10.1167/iovs.04-1369. View

16.

Suh Y, Afaq F, Khan N, Johnson J, Khusro F, Mukhtar H . Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis. 2010; 31(8):1424-33. PMC: 2915634. DOI: 10.1093/carcin/bgq115. View

17.

Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Suemura M . Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J Allergy Clin Immunol. 2003; 111(6):1299-306. DOI: 10.1067/mai.2003.1456. View

18.

Crozier A, Burns J, Aziz A, Stewart A, Rabiasz H, Jenkins G . Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability. Biol Res. 2005; 33(2):79-88. DOI: 10.4067/s0716-97602000000200007. View

19.

Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H . Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol. 2010; 108(2):84-93. DOI: 10.1111/j.1742-7843.2010.00613.x. View

20.

Chen Y, Shen S, Lee W, Lin H, Ko C, Shih C . Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol. 2002; 76(5-6):351-9. DOI: 10.1007/s00204-002-0346-6. View